Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
BRL-50481
Другие языки:

    BRL-50481

    Подписчиков: 0, рейтинг: 0
    BRL-50481
    BRL-50,481.svg
    Clinical data
    ATC code
    • None
    Identifiers
    • N,N,2-Trimethyl-5-nitrobenzenesulfonamide
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C9H12N2O4S
    Molar mass 244.27 g·mol−1
    3D model (JSmol)
    • Cc1ccc(N(=O)=O)cc1S(=O)(=O)N(C)C
    • InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3 ☒N
    • Key:IFIUFCJFLGCQPH-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 family. PDE7 activity is encoded by two genes, PDE7A and PDE7B. BRL-50481 actually shows about an 80-fold preference for the PDE7A subtype, for which it was developed, over PDE7B. BRL-50481 has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.


    Новое сообщение